SEO URLwww.firestrike.ai/deals/travere-therapeutics-palisades-investment-partners-acquisition-2026
acquisitionAnnounced · Jan 24, 2026BiopharmaceuticalSource · SpeculativeArticle · Factual
Palisades Investment Partners acquires Travere Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$5.26M
Target
Travere Therapeutics
NASDAQ: TVTX · San Diego, California
Acquirer
Palisades Investment Partners
Financial Stake
Status
Completed
Palisades Investment Partners agreed to acquire Travere Therapeutics. Reported deal value: $5.26M. Status: Completed. Sector: Biopharmaceutical. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-24. Figures and status may change as filings and press coverage update.
Fool New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company growth potential
Deal timeline
Announced
Jan 24, 2026 · intellectia.ai
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biopharmaceutical with a reported deal value of $5.26M. Figures and status may change as sources update.
Sources: intellectia.ai · Primary article · FireStrike proprietary index